Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review

Abstract

Dalbavancin is a novel lipoglycopeptide antibiotic, characterized by a broad spectrum of activity against Gram-positive cocci. However, its efficacy in spondylodiscitis treatment is not fully established. All adult patients diagnosed with spondylodiscitis and treated with dalbavancin were included across four Italian medical centers from January 2018 to April 2021. We collected clinical and laboratory data, and presented follow-up findings along with a thorough literature review. 13 patients (mean age= 65 years) were included in this study. Dalbavancin was administered as first line treatment in six (46%) of the patients. Reasons for using Dalbavancin included treatment simplification (62%) and clinical failure of previous antibiotics (23%). In general, Dalbavancin was well tolerated with minimal adverse events, and clinical success was achieved in 11/13 (85%) of the patients during hospitalization with additional antibiotics required in the remaining two cases. Five months after discharge, no mortality was observed, however, 42% of patients required additional antibiotics for signs of infection on follow-up imaging. Our study suggests that Dalbavancin could be an effective and safe option in treating spondylodiscitis, however, the scarcity of studies on the topic is concerning. Thus, further studies with large samples and long-term follow-up are warranted to compare the efficacy of Dalbavancin with other available treatment options.

Keywords:

• Dalbavancin
• spondylodiscitis
• treatment
• antibiotic
• case series
• osteoarticular infection
• vertebral osteomyelitis

Disclosure statement

EDM reports research funding for his Institution from MSD, Pfizer, Advanz pharma, Nordic pharma, and personal fees or participation in advisory boards of Roche, Genentech, Pfizer, MSD, Angelini, Advanz pharma, Nordic pharma, Shionogi, Bio-Merieux, Abbvie, Sanofi-Aventis, Medtronic, and DiaSorin. The other authors have no conflicts of interest to disclose.